A phase II evaluation of pemetrexed (ALIMTA, LY231514, IND#40061) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group

摘要: e16507 Background: To estimate the anti-tumor activity of pemetrexed in patients with advanced or recurrent carcinoma endometrium that failed on higher priority treatment protocols and to determine nature degree toxicity. Methods: A multicenter phase II trial was conducted by Gynecologic Oncology Group (GOG). Patients must have had measurable one prior chemotherapy regimen. Pemetrexed at a dose 900 mg/m2 be administered as an IV infusion over 10 minutes every 21 days. Results: From May 1, 2006 July 31, 2007, 27 were entered ten member institutions GOG. total 101 cycles 27% receiving five more cycles. The well tolerated overall. More serious toxicities (grade 3 4) included anemia 19%, leukopenia 38%, neutropenia 46%, constitutional 19%. No related deaths reported. One patient (4%) partial respons...